Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD of SYHA1402 in Healthy Subjects
NCT03988413Phase 1Completed
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Aug 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of syha1402 in diabetic peripheral neuropathy (DPN) (7 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Change of systolic blood pressure, diastolic blood pressure, heart rate, pulse, body temperature at 72 hours, Change of 12-lead ECG at 72 hours and 2 more. Started Aug 2019; status: completed.
02
Drugs
syha1402
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT03988413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03988413.